EcoDrugPlus


Trade Names	ELOXATIN OXALIPLATIN
Synonyms	Eloxatin JM-83 L-OHP MBP-426 (LIPOSOMAL OXALIPLATIN) NSC-266046 Oxaliplatin RP-54780 SR-96669 Xaliplatin
Status
Molecule Category	UNKNOWN
ATC	L01XA03
UNII	04ZR38536J

Trade Names

ELOXATIN

OXALIPLATIN

Synonyms

Eloxatin

JM-83

L-OHP

MBP-426 (LIPOSOMAL OXALIPLATIN)

NSC-266046

Oxaliplatin

RP-54780

SR-96669

Xaliplatin

Status

Molecule Category

UNKNOWN

ATC

L01XA03

UNII

04ZR38536J


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Property Name	Value
Molecular Formula	C8H12N2O4Pt
Molecular Weight	395.27
AlogP	None
Hydrogen Bond Acceptor	None
Hydrogen Bond Donor	None
Number of Rotational Bond	None
Polar Surface Area	None
Molecular species	None
Aromatic Rings	None
Heavy Atoms	None

Property Name

Value

Molecular Formula

C8H12N2O4Pt

Molecular Weight

395.27

AlogP

None

Hydrogen Bond Acceptor

None

Hydrogen Bond Donor

None

Number of Rotational Bond

None

Polar Surface Area

None

Molecular species

None

Aromatic Rings

None

Heavy Atoms

None

Mechanism of Action	Action	Reference
DNA inhibitor	INHIBITOR	DailyMed

Mechanism of Action

Action

Reference

DNA inhibitor

INHIBITOR

DailyMed

Resources	Reference
ChEMBL	CHEMBL414804
FDA SRS	04ZR38536J
Guide to Pharmacology	7433
PubChem	9887054

Resources

Reference

ChEMBL

CHEMBL414804

FDA SRS

04ZR38536J

Guide to Pharmacology

7433

PubChem

9887054


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

OXALIPLATIN

Physicochemical Descriptors

Bioactivity

Cross References